BioNTech (BNTX)
(Real Time Quote from BATS)
$86.93 USD
-1.16 (-1.32%)
Updated Apr 25, 2024 02:10 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
BioNTech SE Sponsored ADR (BNTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$112.62 | $171.00 | $90.00 | 27.85% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for BioNTech SE Sponsored ADR comes to $112.62. The forecasts range from a low of $90.00 to a high of $171.00. The average price target represents an increase of 27.85% from the last closing price of $88.09.
Analyst Price Targets (13)
Broker Rating
BioNTech SE Sponsored ADR currently has an average brokerage recommendation (ABR) of 2.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 2.33 a month ago based on 15 recommendations.
Of the 14 recommendations deriving the current ABR, five are Strong Buy, representing 35.71% of all recommendations. A month ago, Strong Buy represented 40%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 6 | 6 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 8 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.43 | 2.43 | 2.33 | 2.33 | 2.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/17/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
3/21/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Strong Buy |
3/21/2024 | Canaccord Genuity | William Maughan | Strong Buy | Strong Buy |
11/7/2023 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.43 |
ABR (Last week) | 2.43 |
# of Recs in ABR | 14 |
Average Target Price | $112.62 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -0.41 |